| Filed On | Filing |
|---|---|
| 17 Apr 2026 |
8-K/A: Other Events
On April 8, 2026, the Company issued a press release announcing (the “Public Announcement”) that it received Clinical Trial Notification acknowledgement from Australia’s Therapeutic Goods Administration and ethics approval from a Human R... |
| 07 Dec 2022 |
8-K/A: Departure/Election of Directors or Officers; Compensation
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS EXHIBIT MARKED BY [***] HAS BEEN OMITTED BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL |
| 01 Feb 2022 |
8-K/A: Submission of Matters to a Vote of Security Holders
On January 31, 2022, iBio, Inc. (the “Company”) reconvened its 2021 Annual Meeting of Stockholders (the “Annual Meeting”), which had previously been adjourned on December 9, 2021 and again on December 22, 2021 to allow more stockholders ... |
| 13 Oct 2020 |
8-K/A: Shareholder Director Nominations; Other Events
To the extent applicable, the information in Item 8.01 of this Form 8-K is incorporated by reference into this Item 5.08. |
| 19 Mar 2020 |
8-K/A: Other Events
NOTE: Certain information indicated with [***] in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. |
| 25 Feb 2020 |
8-K/A: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities
On February 20, 2020, iBio, Inc., a Delaware corporation (the “Company”), entered into a warrant exchange and amendment agreement (the “Exchange Agreement”) with certain holders (the “Participating Holders”) of the Company’s Series A war... |
Loading...